Desai RJ, et al. - Researchers gauged the risk of venous thromboembolism (VTE) with tofacitinib vs tumor necrosis factor (TNF)-inhibitors in rheumatoid arthritis (RA) patients. They pooled HRs across databases with inverse variance meta-analytic method. In conclusion, they noted infrequent occurrence of VTE in a total of 50,865 RA patients initiating tofacitinib or a TNF inhibitor. Risk of VTE for tofacitinib vs TNF-Is in RA patients was numerically higher, but statistically non-significant. No significant differences was seen in PS-adjusted HRs in the risk of VTE between tofacitinib and TNF-Is in either database with a pooled HR (95% CI) of 1.33.